Cancer immunotherapy has been accompanied by promising results over the past few
years. Programmed Cell Death Protein 1 (PD-1) plays a vital role in inhibiting immune …

Peptides exhibit lower affinity and a shorter half-life in the body than antibodies. Conversely,
peptides demonstrate higher efficiency in tissue penetration and cell internalization than …

Simple Summary The tumor immune escape mechanisms are key factors in cancer
progression and metastasis. They are an undeniable hurdle for successful cancer treatment …

Immune checkpoints are inhibitory receptor/ligand pairs regulating immunity that are
exploited as key targets of anti-cancer therapy. Although the PD-1/PD-L1 pair is one of the …

Blockade of PD-L1 expression on tumor cells via anti–PD-L1 monoclonal antibody (mAb)
has shown great promise for successful cancer treatment by overcoming T-cell exhaustion; …

Programmed death-ligand 1 (PD-L1) is an immune checkpoint inhibitor that binds to its
receptor PD-1 expressed by T cells and other immune cells to regulate immune responses; …

Recent breakthrough results from immune checkpoint inhibitors (ICI) have paved the way to
a new era of cancer immunotherapy. In particular, inhibition of programmed death-1 (PD …

While immunotherapy holds great promise for combating cancer, the limited efficacy due to
an immunosuppressive tumor microenvironment and systemic toxicity hinder the broader …

An in-depth understanding of immune escape mechanisms in cancer is likely to lead to
innovative advances in immunotherapeutic strategies. However, much remains unknown …

Background Progranulin (PGRN), as a multifunctional growth factor, is overexpressed in
multiple tumors, but the role of PGRN on tumor immunity is still unclear. Here, we studied the …